Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5543152 | ACROTECH | Sphingosomes for enhanced drug delivery |
Jun, 2014
(10 years ago) | |
US5814335 | ACROTECH | Sphingosomes for enhanced drug delivery |
Jun, 2014
(10 years ago) | |
US5741516 | ACROTECH | Sphingosomes for enhanced drug delivery |
Jun, 2014
(10 years ago) | |
US6723338 | ACROTECH | Compositions and methods for treating lymphoma |
Mar, 2020
(4 years ago) | |
US7887836 | ACROTECH | Compositions and methods for treating lymphoma |
Mar, 2020
(4 years ago) | |
US7247316 | ACROTECH | Compositions and methods for treating lymphoma |
Sep, 2020
(3 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 09, 2015 |
Orphan Drug Exclusivity(ODE-28) | Aug 09, 2019 |
Orphan Drug Exclusivity(ODE) | Aug 09, 2019 |
Drugs and Companies using VINCRISTINE SULFATE ingredient
Market Authorisation Date: 09 August, 2012
Treatment: Treatment of adult patients with philadelphia chromosome-negative(ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukem...
Dosage: INJECTABLE, LIPOSOMAL